Abstract
The endothelium entered the field of regenerative medicine with the discovery of endothelial progenitor cells (EPCs). These cells participate in endothelial homeostasis and are actively involved in physiological and pathological neovascularization. Despite the unresolved discussion about the very phenotype of these cells, great efforts have been devoted to study the role of EPCs in cardiovascular diseases. EPCs are very rare in peripheral circulation and are further reduced in association with cardiovascular diseases. Therefore, finding therapies to improve EPCs could unleash the way to promising cell-based therapies. Ex-vivo expansion of EPCs is a critical step to augment EPCs number, but it still needs several improvements. An alternative strategy to partially overcome these limitations is to target EPCs with available drugs. In this review we will discuss how disparate pharmacological compounds have been used to improve EPCs number and functions.
Keywords: Endothelium, stem cells, regeneration, treatment
Cardiovascular & Hematological Disorders-Drug Targets
Title: Pharmacologic Targeting of Endothelial Progenitor Cells
Volume: 10 Issue: 1
Author(s): Mattia Albiero, Lisa Menegazzo, Angelo Avogaro and Gian P. Fadini
Affiliation:
Keywords: Endothelium, stem cells, regeneration, treatment
Abstract: The endothelium entered the field of regenerative medicine with the discovery of endothelial progenitor cells (EPCs). These cells participate in endothelial homeostasis and are actively involved in physiological and pathological neovascularization. Despite the unresolved discussion about the very phenotype of these cells, great efforts have been devoted to study the role of EPCs in cardiovascular diseases. EPCs are very rare in peripheral circulation and are further reduced in association with cardiovascular diseases. Therefore, finding therapies to improve EPCs could unleash the way to promising cell-based therapies. Ex-vivo expansion of EPCs is a critical step to augment EPCs number, but it still needs several improvements. An alternative strategy to partially overcome these limitations is to target EPCs with available drugs. In this review we will discuss how disparate pharmacological compounds have been used to improve EPCs number and functions.
Export Options
About this article
Cite this article as:
Albiero Mattia, Menegazzo Lisa, Avogaro Angelo and Fadini P. Gian, Pharmacologic Targeting of Endothelial Progenitor Cells, Cardiovascular & Hematological Disorders-Drug Targets 2010; 10 (1) . https://dx.doi.org/10.2174/187152910790780087
DOI https://dx.doi.org/10.2174/187152910790780087 |
Print ISSN 1871-529X |
Publisher Name Bentham Science Publisher |
Online ISSN 2212-4063 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Blood Biomarkers in Cardioembolic Stroke
Current Cardiology Reviews Low Levels of High Density Lipoprotein Increase the Severity of Cerebral White Matter Changes:Implications for Prevention and Treatment of Cerebrovascular Diseases
Current Alzheimer Research Role of Statins in New-onset Diabetes Mellitus: The Underlying Cause, Mechanisms Involved, and Strategies to Combat
Current Drug Targets Flavonoids as Multi-Target Compounds in Drug Discovery
Mini-Reviews in Organic Chemistry Genetic Mapping of Pharmacogenetic Regulatory Variation
Current Pharmaceutical Design Osteoblastic Responses to LPS, Glucose-oxidised LDL and Minocycline: Therapeutic Targets for Periodontal and Cardiometabolic Diseases
Recent Patents on Endocrine, Metabolic & Immune Drug Discovery Modulation of Stem Cell Differentiation by the Influence of Nanobiomaterials/ Carriers
Current Stem Cell Research & Therapy The Effect of SEX/Gender on Cardiovascular Pharmacology
Current Pharmaceutical Design Chronic Kidney Disease - Different Role for HDL?
Current Medicinal Chemistry Complications of the Type 2 Diabetes Mellitus
Current Cardiology Reviews Helicobacter Pylori Infection, Immune Response and Vaccination
Current Drug Targets - Immune, Endocrine & Metabolic Disorders Apolipoprotein(a) in the Carotid Artery Plaque: Evidence for Proteolytic and Pro-Inflammatory Modifications
Vascular Disease Prevention (Discontinued) Emerging Concepts for Myocardial Late Gadolinium Enhancement MRI
Current Cardiology Reviews Seaweed Proteins as a Source of Bioactive Peptides
Current Pharmaceutical Design Inhibition of Transcription Factors by Plant-Derived Compounds and their Implications in Inflammation and Cancer
Current Pharmaceutical Design Inflammation Fueling Atrial Fibrillation Substrate: Seeking Ways to "Cool" the Heart
Medicinal Chemistry Patent Annotations
Recent Patents on Cardiovascular Drug Discovery Aquaporin-1 and Sodium-Hydrogen Exchangers as Pharmacological Targets in Diabetic Atherosclerosis
Current Drug Targets Considering Circadian Pattern of Blood Pressure in the Treatment of Hypertension via Chronotherapy: A Conducive or Maladroit Approach
Current Drug Targets Chalcones as Versatile Synthons for the Synthesis of 5- and 6-membered Nitrogen Heterocycles
Current Organic Chemistry